SLS - Company ID 0001390478
SELLAS Life Sciences Group, Inc. (SLS) reported net income of -$26.86M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$26.86M | +13.0% |
| FY 2024 | -$30.88M | +17.3% |
| FY 2023 | -$37.34M | +9.6% |
| FY 2022 | -$41.30M | -99.5% |
| FY 2021 | -$20.70M | -23.5% |
| FY 2020 | -$16.76M | +13.1% |
| FY 2019 | -$19.29M | +30.3% |
| FY 2018 | -$27.67M | -16.5% |
| FY 2017 |
SELLAS Life Sciences Group, Inc. (SLS) reported net income of -$26.86M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, SELLAS Life Sciences Group, Inc.'s net income declined from -$11.48M to -$26.86M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$23.75M |
| -34.3% |
| FY 2016 | -$17.68M | +72.3% |
| FY 2015 | -$63.90M | -74.6% |
| FY 2014 | -$36.61M | +52.3% |
| FY 2013 | -$76.68M | -119.3% |
| FY 2012 | -$34.97M | -204.5% |
| FY 2011 | -$11.48M | - |